Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniela Simian Marín"'
Autor:
Allyson Cid Alcayaga, Pamela Gil Galleguillos, Delfina Pradelli Mancino, Josefa Fonck Rojas, Rocío Jofré Zubicueta, Daniela Simian Marín, Francisco Silva Ojeda, Juan Pablo Roblero Cum
Publikováno v:
Annals of Hepatology, Vol 29, Iss , Pp 101708- (2024)
Conflict of interest: No Introduction and Objectives: Infections are a frequent cause of decompensation in patients with liver cirrhosis (LC). Understanding local microbiology is important for the correct choice of antibiotics and achieving good clin
Externí odkaz:
https://doaj.org/article/353caf89387f4f208cd7181dbcfdb9ae
Autor:
Vicente Arancibia Aguilera, Jaime Poniachik Teller, Daniela Simian Marin, Máximo Cattaneo Buteler, Álvaro Urzúa Manchego, MATÍAS MARTÍNEZ OLGUÍN
Publikováno v:
Annals of Hepatology, Vol 29, Iss , Pp 101680- (2024)
Conflict of interest: No Introduction and Objectives: Liver transplantation is the only curative procedure for liver cirrhosis, where pharmacotherapeutic factors are crucial to avoid complications. Transplant rejection is an adverse event that endang
Externí odkaz:
https://doaj.org/article/fb67958aaedc45be87bad14961b6e733
Autor:
Rocío Sedano Muñoz, Gonzalo Pizarro Jofré, Jaime Lubascher Correa, Rodrigo Quera Pino, Daniela Simian Marín
Publikováno v:
Gastroenterología y Hepatología (English Edition). 42:133-140
Anti-tumour necrosis factor α therapy in inflammatory bowel disease has been shown to be effective in clinical practice. After more than a decade using these therapies the question arises about whether there is an appropriate time to suspend these t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce744cf7328ab3a63fc2cdf45047716
https://doi.org/10.1016/j.gastre.2019.02.013
https://doi.org/10.1016/j.gastre.2019.02.013
Autor:
Jaime Lubascher Correa, Daniela Simian Marín, Rodrigo Quera Pino, Gonzalo Pizarro Jofré, Rocío Sedano Muñoz
Publikováno v:
Gastroenterología y Hepatología. 42:133-140
Resumen La efectividad de la terapia con farmacos antifactor de necrosis tumoral α en la enfermedad inflamatoria intestinal ha sido probada en la practica clinica. Tras mas de una decada de uso de este tipo de farmacos, surge la interrogante acerca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fed1dad69c790fb516b3d959c6bbae5
https://doi.org/10.1016/j.gastrohep.2018.10.010
https://doi.org/10.1016/j.gastrohep.2018.10.010